)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
Neuren Pharmaceuticals
Neuren Pharmaceuticals (NEU) investor relations material
Neuren Pharmaceuticals AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 summary27 May, 2026
Opening remarks and agenda
Meeting opened with housekeeping and agenda overview, including CEO and Chair addresses, formal business, and Q&A session.
Hybrid meeting format enabled global shareholder participation.
Financial performance review
Royalty income for 2025 reached AUD 65 million, up 15% year-on-year; profit after tax was AUD 30 million.
Cash and short-term investments rose to AUD 296 million; net cash from operations was AUD 125 million.
Cumulative licensing income from DAYBUE reached AUD 525 million since April 2023.
DAYBUE net sales in 2025 were $391 million, up 12%; Q1 2026 sales hit $101 million, up 20% year-on-year.
2026 royalty income projected at $50–54 million (AUD 70–77 million), with strong growth expected.
Board and executive committee updates
Board and executive team introduced, including CEO, CFO, and Non-Executive Directors.
Executive team highlighted for expertise in rare disease drug development and regulatory affairs.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Neuren Pharmaceuticals
- DAYBUE™ sales and royalties grew in Q2 2024, with strong pipeline and global expansion progress.NEU
Q2 202411 Jun 2026 - Profit after tax surged to A$15 million, with strong DAYBUE royalties and pipeline advances.NEUH1 202511 Jun 2026
- 2025 royalty income rose 15% to A$65 million, with strong DAYBUE sales and pipeline advances.NEUH2 202511 Jun 2026
- Record AUD 166m income, robust DAYBUE growth, and strong pipeline progress in 2024.NEUH2 202411 Jun 2026
- Share buyback of up to 5% approved, with strong cash flows and key clinical programs advancing.NEUInvestor update12 Feb 2026
- NNZ-2591 showed significant safety and efficacy in Angelman syndrome, especially in younger children.NEUStudy Result2 Feb 2026
- FDA supports pivotal phase III trial for rare disorder; final endpoints pending data.NEUStudy Result19 Jan 2026
- Strong Daybue sales and NNZ-2591 pipeline drive financial strength and global expansion.NEU43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026
- Record results and global expansion drive pipeline progress and strong governance support.NEUAGM 202519 Nov 2025
Next Neuren Pharmaceuticals earnings date
H1 202628 Aug, 2026
Neuren Pharmaceuticals
Next Neuren Pharmaceuticals earnings date
H1 202628 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage